Redeye comments on the outcome of AlzeCure’s rights issue, which was significantly oversubscribed at 212%, raising net SEK55.5m. The strong investor interest, combined with the exercise of the overallotment option, reflects growing market confidence in the company’s pipeline and strategic direction.
LÄS MER
